# Spirogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spirogen

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.spirogen.com
- Total disclosed funding: $12M
- Latest round: Series B (May 16, 2003)
- Investors on record: 5

## About

Spirogen is a biopharmaceutical company engaged in the development of innovative therapies, particularly focusing on antibody-drug conjugates to address critical medical needs in oncology and other therapeutic areas.Founded in 2000 and headquartered in London, UK, Spirogen specializes in developing advanced therapeutic solutions. The company was acquired by MedImmune, Inc. in October 2013 for USD 200 mn, with potential additional payments of up to USD 240 mn based on developmental milestones. The acquisition aims to facilitate the clinical launch of MedImmune's antibody-drug conjugates.Spirogen is involved in the research and development of innovative biopharmaceutical products, particularly in the area of oncology. The company focuses on creating antibody-drug conjugates that target and deliver treatments directly to cancer cells, thus enhancing treatment efficacy while minimizing side effects. Their products are utilized within various healthcare systems globally, catering to a wide array of oncological conditions.In 2022, Spirogen reported no revenue, with an EBITDA of USD -43,258 for the most recent year, indicating a focus on development rather than immediate commercial sales.Looking ahead, Spirogen plans to leverage the resources from its acquisition by MedImmune, Inc. to support the clinical development of its antibody-drug conjugates. The strategy includes expanding its product pipeline and launching new therapies aimed at oncology treatments. Additionally, the company is expected to utilize the funding received from MedImmune to enhance its research capabilities and explore international market entries to widen patient access to its innovative therapies.

## Funding rounds

- Series B, May 16, 2003, $10M — Research Corporation Technologies, Ipsen
- Series A, Sep 16, 2002, $0.5M — Bloomsbury Bioseed Fund, CRIL
- Series A, Feb 26, 2001, $1.4M — Research Corporation Technologies, Bloomsbury Bioseed Fund, CRIL, Xenva

## Investors

- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series A, Series B
- Bloomsbury Bioseed Fund (https://capitalatlas.ai/funds/bloomsbury-bioseed-fund) — Series A
- CRIL (https://capitalatlas.ai/funds/cril) — Series A
- Xenva — Series A
- Ipsen — Series B